Citron Pharma LLC today announced that its New Jersey-based business has launched Duloxetine Delayed-Release Capsules USP in 20 mg, 30 mg and 60 mg strengths. Duloxetine Delayed-Release Capsules USP are the generic version of Eli Lilly’s Cymbalta® delayed release capsules, and are indicated for the treatment of major depressive disorder, and generalized anxiety disorder, among other indications. Citron Pharma received final approval from the U.S. Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA) it has exclusively licensed for this product and will begin shipping immediately.
I am pleased to announce our first big launch with Duloxetine Delayed-Release Capsules. We are committed to bringing high quality medications to the market and have put together a team with tremendous industry experience and track record to serve the needs of our customers.
Currently, Citron Pharma has 73 licensed ANDAs pending launch representing $17.5 billion in annual sales, according to IMS Health (2013). Citron Pharma also has seven licensed NDA products pending launch.
Citron Pharma is a recently formed, privately held, US-based pharmaceutical company. The company is focused on developing and marketing both branded and generic products from diverse therapy segments. Citron Pharma’s focus brings a wide portfolio of products to the market from the best of FDA-approved manufacturing facilities in India and the USA. The company’s fully integrated manufacturing network capabilities from API to finished formulation, creates a value chain that drives profitability and extends affordability to its customers. Citron Pharma’s commitment to quality complements its relationship with its manufacturers and quality-conscious customers. Citron Pharma is committed to providing nationwide availability of high-quality branded & generic products through a robust sales, marketing & distribution infrastructure, headquartered in New Jersey.